alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › severity

severity

6 studies tagged severity, dated 2001-01-01 to 2023-09-07. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Correlation of serum complement factor 5a level with inflammatory response and cognitive function in patients with Alzheimer's disease of different severity 2023-09-07
  2. Sex differences in Alzheimer's disease: plasma MMP-9 and markers of disease severity 2022-11-02
  3. The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial 2020-03-06

Studies

6 studies carry this tag.

Date range

2001 to 2023

Top journals

  • Alzheimer's research & therapy 1
  • American journal of Alzheimer's disease and other dementias 1
  • BMC neurology 1
  • Brain : a journal of neurology 1
  • European neurology 1

6 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Correlation of serum complement factor 5a level with inflammatory response and cognitive function in patients with Alzheimer's disease of different severity

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. BMC neurology 2023-09-07 Biomarkers

    Serum C5a level increased with AD severity, and its expression was positively correlated with serum pro-inflammatory factor levels, and negatively correlated with cognitive function.

  2. Sex differences in Alzheimer's disease: plasma MMP-9 and markers of disease severity

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. Alzheimer's research & therapy 2022-11-02 Biomarkers

    MMP-9 may have more detrimental effects on AD-related pathological and cognitive changes in women.

  3. The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. Frontiers in neurology 2020-03-06 Biomarkers

    We examined the effects of a dihydropyridine calcium channel blocker nilvadipine with anti-inflammatory properties on cognition and cerebrospinal fluid (CSF) biomarkers by baseline Alzheimer's disease (AD) severity.

  4. Potential blood biomarker for disease severity in the Taiwanese population with Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. American journal of Alzheimer's disease and other dementias 2012-12-10 Biomarkers

    The identification of blood biomarkers for Alzheimer's disease (AD) could contribute for improvement in early diagnosis.

  5. Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Brain : a journal of neurology 2003-04-01 Biomarkers

    Formalin-fixed brain specimens from sporadic cases with frontotemporal dementia (eight with tau-positive Pick bodies, five with frontotemporal lobar degeneration without inclusions) were compared with those from non-diseased controls (n = 5).

  6. The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer's disease patients and correlates with severity of dementia

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. European neurology 2001-01-01 Biomarkers

    To gain insight of the underlying mechanisms of astroglial response to Alzheimer's disease (AD), the level of glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) from controls and AD subjects were immunochemically determined, and the correlation between that level and dementia severity of AD patients was evaluated.

All topic tags with their study counts